Literature DB >> 2422392

Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus.

K Keegan, M S Collett.   

Abstract

Four distinct antigenic determinants along the G2 glycoprotein encoded by the M segment RNA of the Phlebovirus Rift Valley fever virus were localized. These epitopes were defined by four monoclonal antibodies, three of which were capable of neutralizing virus infectivity; one was nonneutralizing. Immunoprecipitation by these monoclonal antibodies of either denatured or native antigen characterized the epitopes as having linear or higher order structure. Molecular cloning of G2 glycoprotein-coding sequences into a bacterial expression plasmid utilizing a beta-galactosidase fusion protein system was employed for epitope localization. A nuclease BAL 31 plasmid expression library, in which processive regions of the 3' end of the G2 glycoprotein coding sequences were deleted, allowed for approximation of the carboxy-terminal limit of the antigenic determinants. Further subcloning of limited G2 polypeptide sequences into the bacterial expression vector permitted more refined localization of the epitopes. The characteristics of the immunoreactivity of these small peptide regions (between 11 and 34 amino acids) produced in bacteria as G2-beta-galactosidase fusion proteins were similar to those of the authentic Rift Valley fever virus G2 glycoprotein. These defined antigenic determinants and their importance in virus infectivity are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422392      PMCID: PMC252909     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness.

Authors:  L W Laughlin; J M Meegan; L J Strausbaugh; D M Morens; R H Watten
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

3.  Fluorographic detection of radioactivity in polyacrylamide gels with the water-soluble fluor, sodium salicylate.

Authors:  J P Chamberlain
Journal:  Anal Biochem       Date:  1979-09-15       Impact factor: 3.365

4.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

5.  Evidence from recombinant bunyavirus studies that the M RNA gene products elicit neutralizing antibodies.

Authors:  J R Gentsch; E J Rozhon; R A Klimas; L H El Said; R E Shope; D H Bishop
Journal:  Virology       Date:  1980-04-15       Impact factor: 3.616

6.  Biochemical characterization of Rift Valley fever virus.

Authors:  R M Rice; B J Erlick; R R Rosato; G A Eddy; S B Mohanty
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

7.  The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizzotic and virological studies.

Authors:  J M Meegan
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

8.  The Rift Valley fever epizootic in Egypt 1977-78. 2. Ecological and entomological studies.

Authors:  H Hoogstraal; J M Meegan; G M Khalil; F K Adham
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

9.  Complete sequences of the glycoproteins and M RNA of Punta Toro phlebovirus compared to those of Rift Valley fever virus.

Authors:  T Ihara; J Smith; J M Dalrymple; D H Bishop
Journal:  Virology       Date:  1985-07-15       Impact factor: 3.616

10.  An epizootic of Rift Valley fever in Egypt in 1977.

Authors:  J M Meegan; H Hoogstraal; M I Moussa
Journal:  Vet Rec       Date:  1979-08-11       Impact factor: 2.695

View more
  50 in total

1.  Infectious enveloped RNA virus antigenic chimeras.

Authors:  S D London; A L Schmaljohn; J M Dalrymple; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

2.  Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.

Authors:  S J Rosenfeld; K Yoshimoto; S Kajigaya; S Anderson; N S Young; A Field; P Warrener; G Bansal; M S Collett
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 3.  Emerging Infections of CNS: Avian Influenza A Virus, Rift Valley Fever Virus and Human Parechovirus.

Authors:  Clayton A Wiley; Nitin Bhardwaj; Ted M Ross; Stephanie J Bissel
Journal:  Brain Pathol       Date:  2015-09       Impact factor: 6.508

4.  NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture.

Authors:  Sungyong Won; Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

5.  Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

6.  Identification of antigenically important domains in the glycoproteins of Sindbis virus by analysis of antibody escape variants.

Authors:  E G Strauss; D S Stec; A L Schmaljohn; J H Strauss
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  Forms of pp60v-src isolated from Rous sarcoma virus-transformed cells.

Authors:  M S Collett; S K Belzer
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  Acid-activated structural reorganization of the Rift Valley fever virus Gc fusion protein.

Authors:  S M de Boer; J Kortekaas; L Spel; P J M Rottier; R J M Moormann; B J Bosch
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

9.  Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains.

Authors:  Nandadeva Lokugamage; Alexander N Freiberg; John C Morrill; Tetsuro Ikegami
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

Review 10.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.